22,282 Shares in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Acquired by Intech Investment Management LLC

Intech Investment Management LLC bought a new stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) in the third quarter, Holdings Channel.com reports. The institutional investor bought 22,282 shares of the company’s stock, valued at approximately $429,000.

Other large investors also recently added to or reduced their stakes in the company. Sofinnova Investments Inc. increased its holdings in Syndax Pharmaceuticals by 33.9% in the 2nd quarter. Sofinnova Investments Inc. now owns 2,153,669 shares of the company’s stock valued at $44,215,000 after buying an additional 545,129 shares during the period. First Turn Management LLC increased its holdings in shares of Syndax Pharmaceuticals by 85.4% in the third quarter. First Turn Management LLC now owns 1,187,165 shares of the company’s stock valued at $22,853,000 after purchasing an additional 546,776 shares in the last quarter. Millennium Management LLC boosted its holdings in Syndax Pharmaceuticals by 56.3% in the second quarter. Millennium Management LLC now owns 1,065,508 shares of the company’s stock valued at $21,875,000 after acquiring an additional 383,634 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. acquired a new position in Syndax Pharmaceuticals during the 3rd quarter valued at about $15,165,000. Finally, Federated Hermes Inc. boosted its stake in shares of Syndax Pharmaceuticals by 21.8% in the 2nd quarter. Federated Hermes Inc. now owns 656,250 shares of the company’s stock valued at $13,473,000 after purchasing an additional 117,536 shares during the last quarter.

Syndax Pharmaceuticals Stock Performance

Syndax Pharmaceuticals stock opened at $16.70 on Tuesday. The firm’s fifty day moving average price is $18.41 and its 200-day moving average price is $19.76. Syndax Pharmaceuticals, Inc. has a fifty-two week low of $15.00 and a fifty-two week high of $25.34. The stock has a market cap of $1.43 billion, a P/E ratio of -4.60 and a beta of 0.92.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.13) by $0.15. The company had revenue of $12.50 million during the quarter, compared to analysts’ expectations of $9.16 million. During the same quarter last year, the business earned ($0.73) earnings per share. Sell-side analysts predict that Syndax Pharmaceuticals, Inc. will post -2.39 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on SNDX shares. Stifel Nicolaus increased their target price on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a “buy” rating in a research note on Monday, October 14th. StockNews.com lowered shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 23rd. JPMorgan Chase & Co. increased their target price on shares of Syndax Pharmaceuticals from $33.00 to $38.00 and gave the stock an “overweight” rating in a report on Thursday, November 21st. Barclays boosted their price target on shares of Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an “overweight” rating in a report on Thursday, August 15th. Finally, UBS Group initiated coverage on Syndax Pharmaceuticals in a research note on Thursday, October 24th. They issued a “buy” rating and a $37.00 target price for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, Syndax Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $37.64.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).